Business Description
Kodiak Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US50015M1099
Total Employee Number:
124Description
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.03 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 0.5 | |||||
Debt-to-EBITDA | -0.27 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 14.8 | |||||
3-Year EPS without NRI Growth Rate | 12.2 | |||||
3-Year FCF Growth Rate | 19.2 | |||||
3-Year Book Growth Rate | -32.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 39.56 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 100 | |||||
9-Day RSI | 100 | |||||
14-Day RSI | 100 | |||||
3-1 Month Momentum % | 75 | |||||
6-1 Month Momentum % | 75 | |||||
12-1 Month Momentum % | 1368.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.54 | |||||
Quick Ratio | 3.54 | |||||
Cash Ratio | 3.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.7 | |||||
Shareholder Yield % | 0.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -244.19 | |||||
ROA % | -80.64 | |||||
ROIC % | -152.35 | |||||
3-Year ROIIC % | -256.15 | |||||
ROC (Joel Greenblatt) % | -180.33 | |||||
ROCE % | -93.71 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 22.78 | |||||
Price-to-Tangible-Book | 22.84 | |||||
EV-to-EBIT | -10.66 | |||||
EV-to-EBITDA | -12.01 | |||||
EV-to-Forward-Revenue | 42.66 | |||||
EV-to-FCF | -16.6 | |||||
Earnings Yield (Greenblatt) % | -9.38 | |||||
FCF Yield % | -5.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kodiak Sciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | |||
| EPS (TTM) (MXN) | -76.525 | ||
| Beta | -0.0485 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 5.91 | ||
| Volatility % | 718.33 | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR (MXN) | 0.451645 | ||
| 20-Day SMA (MXN) | 749 | ||
| 12-1 Month Momentum % | 1368.63 | ||
| 52-Week Range (MXN) | 51 - 749 | ||
| Shares Outstanding (Mil) | 62.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kodiak Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kodiak Sciences Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 29 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 11:40 | 749.00 (+0.00%) | ||
| General meeting for 2026 | 2026-06-02 09:00 | 749.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 749.00 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 428.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 428.00 (+0.00%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-12 13:30 | 428.00 (+0.00%) | ||
| 8th Annual Evercore Healthcare Conference in Coral Gables | 2025-12-03 15:00 | 400.00 (+0.00%) | ||
| Jefferies Global Healthcare Conference in London, UK | 2025-11-17 08:30 | 51.00 (+0.00%) |
Show
Entries
Kodiak Sciences Inc Frequently Asked Questions
What is Kodiak Sciences Inc(MEX:KOD)'s stock price today?
The current price of MEX:KOD is MXN749.00. The 52 week high of MEX:KOD is MXN749.00 and 52 week low is MXN51.00.
When is next earnings date of Kodiak Sciences Inc(MEX:KOD)?
The next earnings date of Kodiak Sciences Inc(MEX:KOD) is 2026-08-13 Est..
Does Kodiak Sciences Inc(MEX:KOD) pay dividends? If so, how much?
Kodiak Sciences Inc(MEX:KOD) does not pay dividend.
Press Release
Articles on Kodiak Sciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers